



PRESSRELEASE

Malmö 30 April 2020

At the Annual General Meeting of New Nordic Healthbrands AB (publ) on 29 April 2020, the following was resolved

Dividend

It was established that the dividend for the financial year 2019 is set at SEK 1.75 per share and that the record date for the dividend shall be 4 May 2020. Payment through Euroclear Sweden AB is expected to be made on 7 May 2020.

Board and fees

All Board members elected by the AGM; Jessica Tyreman, Lennart Sjölund, Marinus Blaabjerg Sørensen and Karl Kristian Bergman Jensen were re-elected by the AGM. As in 2019, the Board comprises four Board members elected by the AGM. Marinus Blaabjerg Sørensen was re-elected Chairman of the Board. It was stipulated that the board fees total of SEK 250,000 to be distributed with SEK 0 to the Chairman of the Board, SEK 0 to Karl Kristian Bergman Jensen and SEK 125,000 each to the other two Board members.

Auditor

Ernst & Young AB was elected auditing company with Martin Henriksson as principal auditor. It was stipulated that remuneration to the auditor should be paid with a reasonable amount according to approved invoice.

Authorization

The Board was authorized, during the period leading up to the next Annual General Meeting, to decide, on one or more occasions, on the issue of new shares, or the issue of convertible debentures or the issue of warrants. By decision based on the authorization, the number of shares can be increased by a maximum of 1,500,000, corresponding to a total increase in the share capital by a maximum of SEK 1,500,000. The authorization shall also include the right to decide on a new issue or issue of convertible debentures or issue of warrants with a stipulation on in kind or set-off right or otherwise with the conditions referred to in Chapter 13. § 5, first paragraph, 6 or 14. § 5, first paragraph 6, or chap. § 5, first paragraph, the Swedish Companies Act. In accordance with the Board's decision, the issues may be made with deviation from the shareholders' preferential rights. The deviation should enable capital to be raised in connection with the continued investment in the Company's business area, including corporate acquisitions. The issue price shall be determined on market terms that are generally applied to similar types of issues.

Malmö in April 2020, the Board of Directors, New Nordic Healthbrands AB (publ)

For more information please contact:

Karl Kristian Bergman Jensen, CEO +46 40-239520.

Marinus Blåbjerg Sørensen, CFO +45 46323344.

New Nordic Healthbrands AB (publ), SE-211 43 Malmö, phone +040-239520, e-mail: investor@newnordic.com.

Org. nr. 556698-0453.

Certified advisor: Mangold Fondkommission AB. +46 8 503 01 550, ca@mangold.se.

New Nordic Healthbrands AB (publ) was founded in 1990 and is listed on Nasdaq First North Growth Market Sweden since 2007. The company's business idea is to offer the most effective and safe dietary supplements, natural medicines and cosmetic products for specific health and beauty needs. New Nordic products are available in 41 countries in pharmacies, health stores, beauty shops and travel retail. New Nordic has its own smaller sales and marketing companies in most European countries, Canada and the United States, to organize local marketing campaigns, serve resellers and serve end customers. In 2019, sales were SEK 453 million. Almost all New Nordic products sold worldwide are manufactured in Scandinavia. For more information, visit www.newnordic.com.